

CHAMPIONS BIOTECHNOLOGY, INC.  
Form 8-K  
January 18, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 14, 2011**

**CHAMPIONS BIOTECHNOLOGY, INC.**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>0-17263</b> (Commission File Number)	<b>52-1401755</b> (IRS Employer Identification No.)
--	--	--

<b>Science and Technology Park at Johns Hopkins</b> <b>855 N. Wolfe Street, Suite 619, Baltimore, MD</b> (Address of Principal Executive Offices)	<b>21205</b> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: **(410) 369-0365**

**Inapplicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 14, 2011, Champions Biotechnology, Inc. (the “**Company**”) announced the resignation of Mark Schonau as Chief Financial Officer effective January 17, 2011. The Company is currently conducting a search for a new Chief Financial Officer.

A copy of the Company’s press release announcing the resignation of Mr. Schonau is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits*

The following exhibits are filed herewith:

Exhibit No.

99.1 Press Release dated January 14, 2011

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CHAMPIONS BIOTECHNOLOGY, INC.**  
(Registrant)

Date: January 18, 2011

By: /s/ Joel Ackerman  
Chief Executive Officer